Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis


Creative Commons License

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., ...More

ANNALS OF NEUROLOGY, vol.77, no.3, pp.425-435, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 77 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.1002/ana.24339
  • Title of Journal : ANNALS OF NEUROLOGY
  • Page Numbers: pp.425-435

Abstract

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.